Clinical Trials Logo

Clinical Trial Summary

The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04962139
Study type Interventional
Source Oneness Biotech Co., Ltd.
Contact Jessica Ho
Phone +886 2 2703 1098
Email jessica.ho@onenessbio.com.tw
Status Recruiting
Phase Phase 3
Start date August 10, 2021
Completion date August 15, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04457752 - Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) Phase 4
Terminated NCT02571738 - Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers Phase 3
Completed NCT00632008 - Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers Phase 3
Recruiting NCT00366132 - Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers Phase 2
Terminated NCT05276401 - Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer Phase 2
Completed NCT03282981 - Beta Adrenergic Antagonist for the Healing of Chronic DFU Phase 3
Completed NCT02098447 - Pilot Study on Auricular Vagus Nerve Stimulation Effects in Chronic Diabetic Wounds N/A
Withdrawn NCT00954343 - Shockwave Treatment of Diabetic Foot Ulcer: Step I N/A